Oligosaccharides

Oligosaccharides: A Comprehensive Reference

1. Identity and Classification

Chemical Definition and Nomenclature

An oligosaccharide (from Ancient Greek olígos, "few," and sákkhar, "sugar") is a saccharide polymer containing a small number — typically three to ten — of monosaccharides (simple sugars). The primary classification of dietary carbohydrates is based on chemistry — the character of individual monomers, degree of polymerization (DP), and type of linkage (alpha or beta), as agreed at the Food and Agriculture Organization/World Health Organization Expert Consultation in 1997. This divides carbohydrates into three main groups: sugars (DP 1–2), oligosaccharides or short-chain carbohydrates (DP 3–9), and polysaccharides (DP ≥10).

Oligosaccharides are low-molecular-weight carbohydrates positioned between monosaccharides and polysaccharides. They can be extracted directly from natural products by physicochemical methods or obtained by chemical synthesis or enzymatic reaction.

Oligosaccharides are named on the grounds of the monomeric units forming their oligomers, which in turn relate to their functional properties. There are two naturally occurring forms: those which are digestible (α-glucans, primarily derived from starch, such as maltodextrin) and those which are non-digestible (non-α-glucans). Non-digestible oligosaccharides are soluble and highly fermentable and are included within the definition of dietary fibre in many countries. They exist naturally in many foods, most commonly as fructans and galacto-oligosaccharides (GOS), which are frequently consumed worldwide as part of a typical modern diet.

Major Classes and Their Chemical Structures

The most widely studied oligosaccharides include fructooligosaccharides (FOS), galacto-oligosaccharides (GOS), lactulose-derived galacto-oligosaccharides (LDGOS), xylooligosaccharides (XOS), arabinooligosaccharides (AOS), and algae-derived marine oligosaccharides (ADMO). Other oligosaccharides found in nature include pectin-derived acidic oligosaccharides (pAOS), maltooligosaccharides (MOS), cyclodextrins (CD), and human milk oligosaccharides (HMO).

• Fructooligosaccharides (FOS): FOS are composed of linear chains of fructose units linked by beta (2–1) bonds. The number of fructose units ranges from 2 to 60 and often terminates in a glucose unit. Nutraceutical FOS is a mixture of oligosaccharides — 1-kestose (GF2), nystose (GF3), and 1-fructofuranosylnystose (GF4) — composed of fructose and glucose.
• Galacto-oligosaccharides (GOS): GOS are formed by β-galactosidase transgalactosylation. GOS is an indigestible food component that can pass through the upper gastrointestinal tract relatively intact and ferment in the colon to produce short-chain fatty acids (SCFAs). GOS consists of short chains of galactose molecules. Human milk is an example of a natural source, and contains oligosaccharides known as human milk oligosaccharides (HMOs), which are derived from lactose.
• Human Milk Oligosaccharides (HMOs): Researchers have currently discovered over 200 molecular structures of HMOs in breast milk. HMOs consist of five monomers: glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc), and N-acetylneuraminic acid (Neu5Ac). All HMOs have lactose (Gal-β-1,4-Glc) at their reducing end. A tripartite classification exists for HMOs: fucosylated neutral types, non-fucosylated neutrals, and sialylated species.
• Raffinose Family Oligosaccharides (RFOs): The raffinose family of oligosaccharides (RFOs) are alpha-galactosyl derivatives of sucrose, and the most common are the trisaccharide raffinose, the tetrasaccharide stachyose, and the pentasaccharide verbascose. RFOs are almost ubiquitous in the plant kingdom, found in a large variety of seeds from many different plant families.
• Xylooligosaccharides (XOS) and Arabinoxylan Oligosaccharides (AXOS): Arabinoxylans (AX) from cereals are cell wall components that constitute an important part of dietary fiber intake in humans. Enzymic hydrolysis of AX yields arabinoxylan-oligosaccharides (AXOS), consisting of arabinoxylooligosaccharides and xylooligosaccharides (XOS).
• Soy Oligosaccharides (SBOS): GOS is naturally found in soybeans and can also be synthesized from lactose. Soy oligosaccharides act to stimulate the growth of Bifidobacterium species in the large intestine and are marketed in Japan as dietary supplements and in functional foods.

Natural Sources

FOS are oligosaccharides that occur naturally in plants such as onion, chicory, garlic, asparagus, banana, and artichoke, among many others. Varieties of sources contain fructooligosaccharides in varying concentrations, including wheat, honey, onion, garlic, and banana. Barley and tomato contain approximately 0.15% FOS, banana and brown sugar approximately 0.30%, and honey approximately 0.75% FOS.

In adults, the main dietary sources of oligosaccharides are chicory, artichokes, onions, garlic, leeks, bananas, and wheat. However, much research has been carried out on purified or synthetic oligosaccharide mixtures, mostly fructooligosaccharides derived from inulin. The normal dietary intake of oligosaccharides is difficult to estimate, as they are not a major dietary component. Around 3 g/day has been suggested in the European diet.

In the composition of human milk's non-liquid components, HMOs rank third in abundance, following closely behind fat and lactose. HMO content changes over the course of lactation, decreasing from approximately 20–25 g/L in colostrum to approximately 10–15 g/L in mature milk.

Commercial Preparations and Forms

FOS emerged in the 1980s as a response to consumers' tendency toward low-calorie sweeteners. Commercially produced FOS are obtained by the extraction and hydrolysis of the inulin molecule present in many plants, and by the enzymatic reaction of transfructosylation of sucrose. Two different classes of FOS mixtures are produced commercially, based on inulin degradation or transfructosylation processes.

FOS can also be synthesized by enzymes of the fungus Aspergillus niger acting on sucrose. Transgalactooligosaccharides (TOS) are produced from D-lactose via the action of the enzyme beta-galactosidase obtained from Aspergillus oryzae.

FOS, GOS, and inulin are sold as nutritional supplements. GOS and FOS are used in the formulation of dairy products, different types of beverages, bakery products, and sweets, converting them into functional foods. Moreover, they are extensively employed in infant formula. FOS has a low sweetness intensity — approximately 0.3–0.6 times sweeter than sucrose — and a low energy content of 1.5 kcal/g.

2. Traditional and Historical Use

FOS was first discovered in 1804 and has been historically used in folk medicine for treating diabetes, constipation, and other human ailments. The history of fructooligosaccharides dates back to over 150 years ago. The modern history of fructans came into existence with their discovery by Rose in 1804.

FOS has been a popular sweetener in Japan and Korea for many years, even before 1990, when the Japanese government established a "Functionalized Food Study Committee" of 22 experts to regulate "special nutrition foods or functional foods." Japan has been a pioneer in the production and consumption of FOS and GOS. It was the first country to incorporate non-digestible oligosaccharides in foods, being a world leader in the use of prebiotics as functional ingredients.

Transgalactooligosaccharides (TOS) are marketed in Japan and Europe as dietary supplements and are used in functional foods. Some GOS-containing foods are certified as Food for Specified Health Uses by the Consumer Affairs Agency in Japan.

In the European Union, fructooligosaccharides (FOS) are regulated as a food ingredient with a history of safe consumption, rather than as a novel food under Regulation (EU) 2015/2283, due to their prior use in member states before 1997. GOS, by contrast, are authorized as novel foods in the EU/UK, as they were not widely consumed before 1997 and therefore have no such extended history of consumption.

FOS can be found in approximately 36,000 different plants, cereals, and honey; however, these sources only provide trace amounts of FOS, resulting in the need for commercial production. Due to the rise in mass FOS production over the last few decades, scientists have been able to examine this increasingly available prebiotic and the food properties and health benefits it exhibits.

3. Key Constituents, Active Compounds, and Mechanisms of Action

Structural Basis of Bioactivity

Biological activity of oligosaccharides is closely related to their chemical structure, including molecular weight, monosaccharide composition, glycosidic bond connection, and position.

Because of the configuration of their glycosidic bonds, fructooligosaccharides resist hydrolysis by salivary and intestinal digestive enzymes. In the colon, they are fermented by anaerobic bacteria. This gives them a lower caloric value while contributing to the dietary fiber fraction of the diet.

Raffinose family oligosaccharides are almost ubiquitous in the plant kingdom. Humans and other monogastric animals do not possess the α-galactosidase (α-GAL) enzyme to break down RFOs, and these oligosaccharides pass undigested through the stomach and upper intestine.

Prebiotic and Bifidogenic Activity

The most well-known effect of most non-digestible oligosaccharides — and in particular fructooligosaccharides — is the selective stimulation of the growth of Bifidobacteria, thus significantly modifying the composition of the colonic microbiota. Such a modification, which has been clearly demonstrated in human volunteers, is considered beneficial in part because it is accompanied by a significant reduction in the number of bacteria reported to have pathogenic potential.

In the context of prebiotics, microbiota balance or activities are modified by oligofructose, galacto-oligosaccharides, FOS, inulin, and lactulose. These have been frequently reported to increase populations of Bifidobacterium and Lactobacillus.

Short-Chain Fatty Acid Production

Dietary FOS are not hydrolyzed by small intestinal glycosidases and reach the cecum structurally unchanged. There, they are metabolized by the intestinal microflora to form short-chain carboxylic acids, L-lactate, CO₂, hydrogen, and other metabolites. Short-chain oligosaccharides are similar to dietary fibers in resisting digestion in the intestine and being converted to acetate, propionate, butyrate, and gas in the colon.

HMOs naturally act as prebiotics, which can be utilized selectively by intestinal bacteria to support the establishment of a balanced gut microbiome. The microbial fermentation of HMOs results in the formation of bacterial metabolites such as short-chain fatty acids (SCFAs) and aromatic lactic acids, which have local and systemic effects.

Epithelial Barrier and Anti-Pathogen Mechanisms

HMOs also act as decoy glycan structures that pathogens bind to, preventing their interaction with cell-surface receptors. Additionally, observational and preclinical studies suggest that HMOs have direct, microbiome-independent effects.

Fucosylated HMOs, such as 2′-FL and 3′-FL, are particularly effective in preventing pathogen adhesion, while sialylated HMOs, including 3′-SL and 6′-SL, provide antiviral protection and immune modulation. Neutral HMOs predominantly act as prebiotics, whereas acidic HMOs exhibit anti-inflammatory and antimicrobial properties.

Immune Modulation

Reported functions of HMOs include anti-infection activity against pathogenic microorganisms, strengthening of colonic barrier function, prevention of necrotizing enterocolitis (NEC), anti-inflammatory immune modulation, and enhancement of infant cognitive ability. Two potential mechanisms have been proposed: functional effects caused by fermentation products of HMOs by colonic beneficial bacteria, and interaction of HMOs with colonic epithelial cells or blood cells during the systemic circulation of HMOs after absorption at low levels.

Various physiological functions of GOS have been reported, including the capacity to stimulate the growth of bifidogenic bacteria in the gut, support normal gut transit, contribute to natural defenses, enhance mineral absorption, and stimulate immune functions and lower inflammation.

Glycemic and Lipid Mechanisms

Indigestible oligosaccharides, as a common dietary fiber, play an important role in regulating the structure and function of the gut microbiota. Their mechanism of action is mainly attributed to their role as a carbon source for specific probiotics, producing related metabolites, and regulating the gut microbial community.

4. Scientific Evidence by Area of Use

4.1 Gut Microbiota Modulation and Prebiotic Effects

Inulin-type fructans (ITF), including short-chain fructooligosaccharides (scFOS), oligofructose, and inulin, are commonly used fibers widely regarded as prebiotics for their ability to be selectively utilized by the intestinal microbiota to confer a health benefit.

Evidence from human clinical trial studies suggests that ITF have a prebiotic effect on the intestinal microbiota, promoting the abundances of Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii. Beneficial health effects following ITF intake include improved intestinal barrier function, improved laxation, increased insulin sensitivity, decreased triglycerides and an improved lipid profile, increased absorption of calcium and magnesium, and increased satiety. Although there is some evidence for differing effects of ITF based on chain length, the lack of direct comparisons and detailed descriptions of physicochemical properties limits the ability to draw conclusions from human clinical studies.

Evidence strength: Moderate-to-strong for bifidogenic effects in humans; moderate for downstream extraintestinal effects.

4.2 Glycemic Control and Metabolic Effects

A 2022 systematic review and meta-analysis published in Food & Function is among the most comprehensive analyses of oligosaccharides and glycemic markers. The objective was to investigate the effect of oligosaccharides on glycemic control markers, including fasting blood glucose (FBG), fasting blood insulin (FBI), glycated hemoglobin (HbA1c), and HOMA-IR, using systematic searches of PubMed, Embase, and the Cochrane Library. A total of 46 randomized controlled trials were included. Oligosaccharides significantly reduced FBG (WMD: −0.295 mmol/L; 95% CI: −0.396 to −0.193; p < 0.001; 46 trials; 2,412 participants), FBI, HbA1c (WMD: −0.365; 95% CI: −0.725 to −0.005; p < 0.05; 11 trials; 661 participants), and HOMA-IR (WMD: −0.793; 95% CI: −1.106 to −0.480; p < 0.001; 24 trials; 1,382 participants). Oligosaccharides were more beneficial for participants with obesity or diabetes than for healthy participants.

Regarding specific oligosaccharide types and glucose metabolism, xylooligosaccharide (XOS) supplementation was found to relieve hyperglycemia, hyperlipidemia, and oxidative status in a randomized double-blind clinical trial. XOS supplementation also reduced glucose, HbA1c, and fructosamine concentrations and regulated abnormal lipid metabolism in type 2 diabetes mellitus.

Chitosan oligosaccharides have also been examined. A randomized, double-blind, controlled crossover trial assigned subjects with impaired glucose tolerance, impaired fasting glucose, and healthy subjects to consume chitosan oligosaccharide (GO2KA1) versus placebo capsules, then consumed 75 g sucrose within 15 minutes. Blood glucose levels were assessed using a 2-hour oral sucrose tolerance test. The antidiabetic and hypoglycemic effects were thereby evaluated in this controlled human model.

Evidence strength: Moderate-to-strong for short-term glycemic marker improvement in people with diabetes or prediabetes. High heterogeneity across trials (I² > 85% for several outcomes) limits firm conclusions for healthy populations.

4.3 Gastrointestinal Health and Bowel Function

Besides their bifidogenic effect, chicory fructooligosaccharides have additional nutritional properties on digestive physiological parameters such as colonic pH and stool bulking, which justify their classification as dietary fibers.

FOS are considered prebiotics, and their use in infant formulas is due to their positive effects on gastrointestinal function. They are reported to increase the fecal Bifidobacterium content to improve problems such as constipation in children who are not breastfed.

A large ongoing clinical study — the Inside Study — is a randomized, double-blind, placebo-controlled multi-centre study investigating the effectiveness of prebiotic oligosaccharides in children aged 1–5 years with functional constipation. The impact on gut microbiome outcomes such as fecal microbiota composition and metabolites are also being investigated. Participants receive supplements for 8 weeks, containing one of two prebiotic oligosaccharides or placebo, followed by a 4-week wash-out period.

Some trials have shown improvement in stool consistency in children with functional constipation after the consumption of prebiotic oligosaccharides. However, the evidence linking oligosaccharide and/or fiber intake to improved symptoms is rather weak. This is not only due to the low number of studies, but also the small sample size, overall poor quality of methods used, and incomplete reporting of results.

For irritable bowel syndrome (IBS), daily intake of a 4:1 mix of 2′-FL and LNnT (HMOs) at doses of 5 g or 10 g over 4 weeks significantly increased Bifidobacterium spp. abundance, modulated fecal and plasma metabolite profiles, and improved IBS symptoms — all without inducing adverse immune or mucosal responses. A more extensive 12-week open-label study involving 317 IBS patients confirmed that daily supplementation with 5 g of the same 4:1 mix improved bowel function, reduced IBS symptom severity, and enhanced quality of life, with only mild gastrointestinal discomforts reported as side effects.

Evidence strength: Moderate for bowel regularity and constipation; early but promising evidence for IBS using HMO blends. Evidence in children with functional constipation remains preliminary.

4.4 Infant Nutrition and Human Milk Oligosaccharides (HMOs)

HMOs, a diverse group of complex sugars, are increasingly recognized for their health advantages for infants. These bioactive molecules are believed to be critical in shaping gut microbiota, infant immunity, and overall health. Recent clinical studies have focused on supplementation of infant formulas with manufactured HMOs to replicate some of the benefits observed in breastfed infants.

A systematic review of manufactured HMO clinical trials identified 26 relevant clinical studies plus five follow-up publications. The clinical trials varied in study populations, including healthy term infants, infants with medical indications, children, and adults. They tested eight different HMO structures individually or as blends in varying doses. All trials included safety and tolerance assessments. The studies consistently found that HMO supplementation was safe and well tolerated. Infant studies reported a shift in outcomes towards those observed in breastfed infants, including stool characteristics, gut microbiome composition, and intestinal immune markers.

Manufactured HMOs are safe, well-tolerated, and show promising benefits for immune health and gut microbiota composition, closely mirroring the effects of natural HMOs found in breast milk. Although studies have explored the prebiotic role of HMOs in modulating neuroactive metabolites such as SCFAs produced by gut microbiota, there is a notable lack of research directly evaluating cognitive outcomes of HMOs using MRI or standardized developmental assessment tools.

Evidence strength: Strong for safety and tolerability; moderate for microbiome and immune effects in infants; cognitive outcomes remain inadequately characterized in clinical trials.

4.5 Immune Function and Allergy Prevention

The specific combination of 90% short-chain (sc)GOS with 10% long-chain (lc)FOS resembles the molecular size distribution of the neutral HMO fraction found in human milk. Prebiotic supplementation with scGOS and lcFOS reduces the incidence of allergy development.

A randomized double-blind placebo-controlled study used a hypoallergenic whey formula with either 8 g/L GOS/FOS in a 9:1 ratio or 8 g/L maltodextrin (placebo) for 6 months in infants at risk for allergy. This study shows that GOS/FOS supplementation induces a beneficial antibody profile. GOS/FOS reduces the total immunoglobulin response and modulates the immune response toward cow's milk protein, while leaving the response to vaccination intact. This suggests that oral GOS/FOS supplementation is a safe method to restrain the atopic march.

The data show a significant effect of a dietary mixture of GOS/FOS on the incidence of atopic dermatitis (AD) at 6 months of age. Although the mechanism of this effect requires further investigation, it appears likely that oligosaccharides modulate postnatal immune development by altering bowel flora and may have a potential role in primary allergy prevention during infancy.

However, the evidence is not without controversy. Other trials did not confirm these positive results. In one study evaluating preterm, low birth weight infants fed a formula containing a prebiotic mixture (GOS/FOS plus acidic oligosaccharides), there was no difference in the prevalence of AD and bronchial hyper-reactivity. In another study, a partially hydrolyzed formula supplemented with specific oligosaccharides induced immunomodulatory effects — such as increased regulatory T-cell numbers — but was not able to reduce AD incidence at 12 or 18 months.

In 2011, the Nutrition Committee of the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) found insufficient evidence to recommend supplementing with prebiotics in infant formulas to prevent atopic disease. The European Academy of Allergology and Clinical Immunology (EAACI) has similarly concluded that there is not enough evidence to recommend prebiotics in allergy prevention. A recent meta-analysis, however, came to an opposing conclusion regarding atopic dermatitis, finding a long-term reduction in its incidence. In conclusion, there is only limited evidence to suggest that prebiotic oligosaccharides prevent atopic dermatitis or decrease its severity.

Evidence strength: Mixed and contested. Some positive RCTs exist, particularly for early-life atopic dermatitis reduction with GOS/FOS, but other well-conducted trials found no benefit. International allergy bodies have not issued definitive recommendations in favor of prebiotics for allergy prevention.

4.6 Mineral Absorption and Bone Health

A growing body of preclinical and clinical literature shows that prebiotics are essential for improving the intestinal absorption of calcium and other minerals and also for enhancing skeletal health. Carefully designed clinical trials with prebiotics have resulted in a better understanding of potential mechanisms by which microbiota impact bone health, but a large gap exists to understand how prebiotics indirectly or directly manipulate the gut–bone axis to prevent or treat age-related bone diseases such as osteoporosis.

Several studies have found that FOS and inulin promote calcium absorption in both the animal and the human gut. FOS oligosaccharides have been recognized to selectively stimulate the growth of prebiotic bacteria along with enhanced calcium and magnesium absorption in the large intestine.

Evidence strength: Preclinical evidence is consistent; human clinical trial evidence for bone outcomes remains limited and confirmatory large trials are lacking.

4.7 Lipid and Cholesterol Metabolism

Oligosaccharides have an ability to decrease cholesterol levels in the serum. Phospholipid and triglyceride levels are also found to be regulated in the serum by prebiotic food. FOS and GOS are noted to be low-caloric sweeteners, contribute to body weight control, and have a low glycemic index.

HMOs are thought to lower the risk of metabolic diseases by promoting a healthy gut microbiota, which is linked to improved glucose metabolism and lipid profiles.

Evidence strength: Preclinical and some clinical data support lipid-lowering effects; the evidence in humans is primarily from short-term RCTs included in broader metabolic endpoints, and definitive high-quality evidence specific to lipid outcomes remains limited.

4.8 Healthy Aging and Cognitive Function

A 6-week randomized controlled trial specifically evaluated HMO supplementation in older adults. This trial evaluated whether 2′-fucosyllactose (2′-FL), a human breast milk oligosaccharide with established benefits in infants and animal models, could improve gut microbiota and immune function in 89 healthy older adults (mean age 67.3 years). While the primary endpoint of cytokine response change was not met, 2′-FL supplementation increased gut Bifidobacterium levels and elevated serum insulin, HDL cholesterol, and FGF21 hormone. Bifidobacterium "responders" experienced additional metabolic and proteomic changes and also performed better on a cognitive test of visual memory. Nonresponders were more likely to lack Bifidobacterium in their gut microbiota at the start of the intervention.

Clinical reviews have also highlighted two novel clinical findings: the potential therapeutic role of HMOs in obesity prevention by promoting fat loss while preserving muscle mass, and their beneficial effects in osteoarthritis by reducing pain and enhancing mobility.

Evidence strength: Preliminary. Cognitive effects and muscle-preservation findings come from small or single trials and require independent replication before any firm conclusions can be drawn.

4.9 Skin Health

In vivo animal studies and clinical trials reveal that prebiotic oligosaccharides, administered orally or topically, alleviate atopic dermatitis, enhance skin hydration, attenuate acne, and protect against photo-aging by modulating the skin–gut microbiota and immune responses. Mechanistically, oligosaccharides mediate these benefits including gut–skin axis crosstalk, immune regulation, and microbial metabolite signaling.

Evidence strength: Largely preclinical and mechanistic. Clinical evidence in skin health is early-stage; replication in large RCTs is needed.

5. Body Systems and Health Areas

• Gastrointestinal System: Prebiotic modulation of colonic microbiota, stool consistency, bowel regularity, colonic pH, short-chain fatty acid production, intestinal barrier integrity, and colonic fermentation.
• Immune System: Modulation of innate and adaptive immunity, reduction of pathogen adhesion, influence on atopic dermatitis incidence, and modulation of the Th1/Th2 immune balance in infants.
• Metabolic System: Glycemic control (FBG, HbA1c, HOMA-IR), lipid metabolism (triglycerides, cholesterol), and body weight regulation.
• Musculoskeletal System: Calcium and magnesium absorption enhancement, potential contributions to bone mineral density via the gut–bone axis.
• Skin: Emerging evidence for benefits in atopic dermatitis, hydration, and photo-aging via the gut–skin axis.
• Infant Development: HMOs support gut microbiome colonization, immune development, and potentially cognitive development in early life.
• Neurological System (emerging): Preliminary evidence for cognitive benefits through microbiota-mediated pathways and SCFA production, especially in aging populations.

Functional oligosaccharides, as an excellent functional food base, can be used as dietary fiber and prebiotics to enrich the diet; improve the microecology of the gut; and exert antitumor, anti-inflammatory, antioxidant, and lipid-lowering properties.

6. Dosage Forms and Reported Clinical Dosages

Oligosaccharides are commercially available in several forms, including powders, capsules, tablets, and as incorporated ingredients in functional foods (dairy products, beverages, infant formula, cereals, bakery items, and confectionery). These oligosaccharides may be added to food and drink products such as milk, yoghurt, desserts, cereals, confectionery, infant formulas, and baby foods.

Reported dosages from clinical studies include:

• IBS (HMO 2′-FL/LNnT blend, 4:1 ratio): Daily intake of 5 g or 10 g over 4 weeks significantly increased Bifidobacterium abundance and improved IBS symptoms.
• IBS (extended open-label study): A 12-week open-label study involving 317 IBS patients confirmed that daily supplementation with 5 g of the same 4:1 mix (2′-FL and LNnT) improved bowel function and reduced IBS symptom severity.
• Infant formula (GOS/FOS): In a double-blind randomized placebo-controlled study, infants received a hypoallergenic whey formula with either 8 g/L GOS/FOS in a 9:1 ratio or 8 g/L maltodextrin (placebo) for 6 months.
• Arabinoxylan oligosaccharides (AXOS) / oligofructose (tolerance study): Twenty healthy volunteers consumed wheat bran extract (WBE, 15 g/day in week one, 30 g/day in week two), oligofructose (15 g/day in week one, 30 g/day in week two), and placebo in a random crossover order, with 2-week washout periods between treatments.
• XOS tolerable dose: At higher levels comparable to sugar consumption in the average Western diet, oligosaccharides such as xylo-oligosaccharides can cause gastrointestinal distress, including diarrhoea, discomfort, and bloating. For xylo-oligosaccharides, the highest tolerated dose has been reported as 12 g/day.
• GOS (tolerability): Reviews on bowel function suggest that doses at or below about 12 g/day of GOS are often well tolerated, although individual response varies.
• HMO (3′-SL, tolerability): In a placebo-controlled trial among dyspeptic adults, daily administration of 3′-SL at 10 g or 20 g was well tolerated.
• 2′-FL in older adults: A 6-week randomized controlled trial evaluated 2′-FL supplementation in 89 healthy older adults (mean age 67.3 years).

Although there are dietary intake recommendations for total dietary fiber, there are no such recommendations for individual non-digestible carbohydrates (NDCs). NDCs are heterogeneous in their chemical composition and physicochemical properties — characteristics that contribute to their tolerable intake levels. Guidance on tolerable intake levels of different NDCs is needed because overconsumption can lead to undesirable gastrointestinal side effects.

7. Safety Considerations and Interactions

Regulatory Safety Status

GOS is certified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration (FDA), with multiple GRAS notices including GRN 233, 236, 285, 286, 334, 484, 489, 495, 518, and 569. Short-chain FOS are being used as functional food and feed ingredients in Europe, America, and Asia due to their GRAS status and have received considerable attention in the nutraceutical sector.

Clinical studies have consistently found that HMO supplementation is safe and well tolerated.

Gastrointestinal Tolerance

The most common side effects are mild gastrointestinal symptoms such as bloating, gas, or temporary abdominal discomfort, especially when a fermentable prebiotic is introduced quickly or at a higher intake.

A review synthesized findings from 103 clinical trials in adults without gastrointestinal disease who reported gastrointestinal effects, including tolerance (e.g., bloating, flatulence, borborygmi/rumbling) and function (e.g., transit time, stool frequency, stool consistency). Studies provided doses ranging from 0.75 to 160 g/day and lasted from a single-meal tolerance test to 28 weeks. Tolerance was NDC specific; thus, recommendations ranged from 3.75 g/day for alginate to 25 g/day for soy fiber.

Specific Type-Level Tolerance Thresholds

It is known that oligosaccharides such as xylo-oligosaccharides can cause gastrointestinal distress, including diarrhoea, discomfort, and bloating at high consumption levels. For xylo-oligosaccharides, the highest tolerated dose has been reported as 12 g/day.

HMO Tolerability at High Doses

At high doses, a mixture of 2′-FL and LNnT showed better tolerability than the individual oligosaccharides alone.

Considerations for Individuals with Lactose Intolerance or Dairy Sensitivity

Supplementation with the prebiotic galacto-oligosaccharides (GOS) could improve gut health and benefit lactose intolerant individuals. GOS is derived from lactose, and individuals with dairy allergies (as distinct from lactose intolerance) should review product labeling, as residual milk proteins may be present depending on the manufacturing process.

Selective Fermentation and Inter-Individual Variability

Due to the selective utilization of oligosaccharides, factors such as the types and structures of oligosaccharides have different impacts on the composition of microbial populations and the production of metabolites in the colon ecosystem. Response to oligosaccharide supplementation may depend substantially on baseline gut microbiota composition; for example, individuals who lacked Bifidobacterium in their gut microbiota at the start of intervention were more likely to be nonresponders.

Drug and Nutrient Interactions

No well-characterized, source-backed pharmacokinetic drug–drug interactions with oligosaccharides have been identified in the peer-reviewed literature reviewed here. The principal interaction concern relates to nutrient absorption: some oligosaccharides have been shown to enhance absorption of calcium and magnesium via colonic fermentation-mediated mechanisms, which could theoretically alter the need for mineral supplementation, though human clinical evidence for this effect remains at the level of dietary physiological modulation rather than a clinically significant pharmacological interaction.

Populations Requiring Attention

NDOs, as prebiotics, show potential in alleviating a variety of human chronic diseases such as diabetes, depression, constipation, colitis, and obesity by modulating the gut microbiota to produce beneficial metabolites. However, the relationship between the precise structure of oligosaccharides and their fermentation state in the gut remains unclear, which limits their application. Individuals with FODMAP-sensitive irritable bowel syndrome may experience exacerbated symptoms at certain oligosaccharide intakes, as FOS and some GOS subtypes are classified within the fermentable carbohydrate groups targeted by low-FODMAP dietary protocols.

References

• Preparation, structural characterization, biological activity, and nutritional applications of oligosaccharides — PubMed (2024)
• Preparation, structural characterization, biological activity, and nutritional applications of oligosaccharides — PMC (2024)
• Carbohydrate terminology and classification — PubMed (2007)
• Health benefits of non-digestible oligosaccharides — PubMed (1997)
• Dietary fructooligosaccharides and potential benefits on health — PubMed (2010)
• Oligosaccharides: a boon from nature's desk — PMC (2016)
• Biological activity of galacto-oligosaccharides: A review — PubMed (2022)
• Clinical Studies on the Supplementation of Manufactured Human Milk Oligosaccharides: A Systematic Review — PMC (2023)
• Clinical evidence and mechanistic pathways of human milk oligosaccharide supplementation: an updated review — PMC (2025)
• The Prebiotic Potential of Inulin-Type Fructans: A Systematic Review — PMC (2022)
• Effect of prebiotic oligosaccharides on bowel habit and gut microbiota in children with functional constipation (Inside study) — PMC (2024)
• A Narrative Review of Human Clinical Trials to Improve Lactose Digestion and Tolerance by Feeding Bifidobacteria or Galacto-Oligosaccharides — PMC (2023)
• Prebiotic Oligosaccharides in Skin Health: Benefits, Mechanisms, and Cosmetic Applications — PMC (2025)
• Effects of oligosaccharides on the markers of glycemic control: a systematic review and meta-analysis of RCTs — Food & Function (2022)
• Chitosan oligosaccharide improves postprandial glycemic response: a crossover, randomized controlled trial — PMC (2019)
• Can functional oligosaccharides reduce the risk of diabetes mellitus? — PMC (2019)
• Prebiotics, Bone and Mineral Metabolism — PMC (2018)
• A human milk oligosaccharide alters the microbiome, circulating hormones, and metabolites in a randomized controlled trial of older adults — PMC (2025)
• Immunomodulation by Human Milk Oligosaccharides: The Potential Role in Prevention of Allergic Diseases — PMC (2020)
• A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age — PMC (2006)
• A specific mixture of scGOS and lcFOS induces a beneficial immunoglobulin profile in infants at high risk for allergy — PubMed (2008)
• The Role of Prebiotics and Probiotics in Prevention of Allergic Diseases in Infants — PMC (2021)
• Prebiotics in infant formula — PMC (2015)
• Gastrointestinal Effects and Tolerance of Nondigestible Carbohydrate Consumption — PMC (2022)
• Tolerance and effect of high doses of arabinoxylan-oligosaccharides and oligofructose on faecal output — PMC (2014)
• Structural features, interaction with the gut microbiota and anti-tumor activity of oligosaccharides — PMC (2022)
• Human milk oligosaccharide secretion dynamics during breastfeeding and its antimicrobial role: A systematic review — PMC (2025)
• Recent advances in the science of human milk oligosaccharides — PMC (2025)
• Technological Aspects of the Production of Fructo and Galacto-Oligosaccharides. Enzymatic Synthesis and Hydrolysis — Frontiers in Nutrition (2019)
• Recent developments in the production of prebiotic fructooligosaccharides using fungal fructosyltransferases — PMC (2024)
• In Vitro Colonic Fermentation Study of Human Milk Oligosaccharides on Gut Microbiota and SCFA Production in Infants — PMC (2024)
• Sialyllactose and Galactooligosaccharides Promote Epithelial Barrier Functioning and Modulate Microbiota and SCFA Production In Vitro — PMC (2019)
• Prebiotic Type Spotlight: Fructooligosaccharides (FOS) — Global Prebiotic Association